Abstract
Vividion Therapeutics has launched based on small-molecule drug discovery technology from three Scripps Research Institute scientists. Backed by $50 million in venture capital funding, Vividion combines a platform for proteome-wide ligand and target discovery from Benjamin F. Cravatt with synthetic chemistry from Phil S. Baran and Jin-Quan Yu. Much drug discovery involves screening of compound libraries using a single target-specific assay. Vividion, in contrast, evaluates compounds in native biological systems, such as human immunocytes and cancer cell lines, so promising protein-ligand interactions are identified amid the entire proteome and in the context of actual protein function.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.